Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ADP-ribosylation factor guanine nucleotide exchange factor 1 (ARFGEF1, also known as BIG1) is a large protein (∼209 kDa) that catalyzes the exchange of GDP for GTP on ADP-ribosylation factors (ARFs), thereby activating them during intracellular vesicular trafficking. ARFGEF1 possesses a Sec7 domain responsible for this exchange activity, which is also the target for inhibition by Brefeldin A. This protein is essential for the maintenance of Golgi apparatus structure, maturation of key glycoproteins such as integrin beta-1, and regulation of cell polarity and movement. Mutations in ARFGEF1 cause a spectrum of neurodevelopmental disorders, marked by developmental delay, intellectual disability, and epilepsy, through mechanisms likely involving haploinsufficiency or loss of function[1][3][5]. ARFGEF1 is thus considered a critical regulator of membrane trafficking and neuronal development.
Inhibition of guanine nucleotide exchange factor activity (e.g., by Brefeldin A; blocks ARF activation by stabilizing GDP-bound form) Potential kinase interactions (as A kinase-anchoring protein, mediating crosstalk between ARF and PKA pathways)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ADP-ribosylation factor guanine nucleotide exchange factor 1 (ARFGEF1).